July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Intravitreal Conbercept or Ranibizumab injections combined with laser therapy for Coats' disease
Author Affiliations & Notes
  • Longli Zhang
    Tianjin Mmedical University Eye Hospital, Tianjin, China
  • Yifeng Ke
    Tianjin Mmedical University Eye Hospital, Tianjin, China
  • Wei Wang
    Hebei Eye Hospital, Xintai, China
  • xiaorong Li
    Tianjin Mmedical University Eye Hospital, Tianjin, China
  • Footnotes
    Commercial Relationships   Longli Zhang, None; Yifeng Ke, None; Wei Wang, None; xiaorong Li, None
  • Footnotes
    Support  Funding/support: This work was supported by the Tianjin Natural Science Foundation (Grant number: 16JCQNJC12700, 15JCZDJC34500) and the National Natural Science Foundation (Grant number: 81500745,81670875).
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5208. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Longli Zhang, Yifeng Ke, Wei Wang, xiaorong Li; Intravitreal Conbercept or Ranibizumab injections combined with laser therapy for Coats' disease. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5208.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The current treatment approaches for Coats’ disease by intravitreal injection of anti- vascular endothelial growth factor (VEGF) agents (Ranibizumab or Conbercept) combined with laser therapy were evaluated for the efficacy during the treatment.

Methods : 32 patients diagnosed with Coats’ disease followed by the treatment with intravitreal anti-VEGF agents and laser therapies at Tianjin Medical University Eye Hospital and Hebei Eye Hospital during July 2012 and January 2017 were reviewed retrospectively. Clinical data were recorded with a minimum follow-up of 6 months. The patients were divided into Ranibizumab-and Conbercept-treated groups, as well as based on age: pediatric and adult groups.

Results : 32 patients were included in this study. The average number of the injections were 2.75± 0.98. Three patients (9%)underwent SRF drainage operation. Laser photocoagulation was conducted on all patients, and the average number of laser were 2.41 ±0. 95. The average follow-up period was 24.38±9.35 months. 18 patients (56%) were stable, 12(38%) patients were improved, 2 patient (6%) showed recurred SRF and exudation. The initial and final BCVA after intravitreal injection of Ranibizumab did not show a significant difference(p=0.07). While BCVA increased after intravitreal injection of Conbercept(p=0.01). The injection and laser durations between Conbercept and Ranibizumab groups did not vary significantly (p=0.11,p=0.38,respectively). 10 patients(67%) in the Ranibizumab-treated group and 7 (50%) in the Conbercept-treated group reached a stable phase, 5(36%) and 7(50%) patients got the vision improved after Ranibizumab-or Conbercept treated, respectively. In pediatric and adult group, the initial and final BCVA differed significantly (p =0.03, p=0.01,respectively).However, the injection numbers was significantly different (p<0.01),while the laser numbers didnot have any significantly difference(p=0.10).

Conclusions : The intravitreal injection of Ranibizumab or Conbercept had no significant adverse effects and change effective, and appeared to offer visual and anatomic improvement in Coats’ disease.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

The fundus image of coats` patient from 2012 to 2017( A-F). A: The initial fundus two months after one shot of laser and intravitreal injection. Telangiectasia and exudative retinal detachment in posterior and peripheral retina. B-F:The fundus change every year after laser and anti-VEGF treatments.

The fundus image of coats` patient from 2012 to 2017( A-F). A: The initial fundus two months after one shot of laser and intravitreal injection. Telangiectasia and exudative retinal detachment in posterior and peripheral retina. B-F:The fundus change every year after laser and anti-VEGF treatments.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×